

Estimate change



TP change



Rating change



Bloomberg	SRF IN
Equity Shares (m)	301
M.Cap.(INRb)/(USD\$b)	626 / 8.1
52-Week Range (INR)	2773 / 1240
1, 6, 12 Rel. Per (%)	-15/8/58
12M Avg Val (INR M)	2454

Financials & Valuations (INR b)

Y/E Mar	2022	2023E	2024E
Sales	124.3	145.0	164.0
EBITDA	31.0	36.5	40.8
PAT	18.2	22.5	25.0
EBITDA (%)	25.0	25.2	24.9
EPS (INR)	61.1	75.7	84.0
EPS Gr. (%)	53.1	23.9	11.0
BV/Sh. (INR)	288	347	414

Ratios

Net D/E	0.3	0.3	0.2
RoE (%)	23.6	23.9	22.1
RoCE (%)	17.2	18.1	17.7
Payout (%)	26.4	22.5	20.2

Valuations

P/E (x)	34.6	27.9	25.1
EV/EBITDA (x)	21.1	18.0	16.1
Div Yield (%)	0.8	0.8	0.8
FCF Yield (%)	0.5	0.6	1.3

Shareholding pattern (%)

As On	Mar-22	Dec-21	Mar-21
Promoter	50.7	50.7	50.8
DII	8.7	9.2	11.2
FII	19.6	19.1	18.4
Others	21.0	21.0	19.6

Note: FII includes depository receipts

CMP: INR2,112 TP: INR2,415 (+14%)
Neutral
Fluorochemicals business drives earnings growth
Earnings in line with our estimates; maintain Neutral

- SRF posted a strong 4QFY22 with revenue growing across all businesses, mainly driven by Chemicals and Packaging segments. Operating performance was primarily led by the Chemicals business (76% of total incremental EBIT YoY).
- Considering the 4QFY22 performance with higher-than-estimated Chemicals EBIT, we upgrade our FY23E/FY24E earnings by 14%/8%, respectively.
- We are encouraged by the long-term structural opportunity in the Chemicals sector. While we certainly believe the company can cash-in on these opportunities, we maintain our **Neutral** stance owing to high valuations, which have been priced into the near-term upside.

Higher Chemicals segment margin drives overall operating performance

- SRF reported overall revenue of INR35.5b (est. of INR35.3b) in 4QFY22, up 36% YoY. EBITDA margin expanded 210bp to 26.4% (est. of 25.8%), primarily led by margin expansion in Chemicals business. EBITDA was at INR9.4b (est. of INR9.1b), up 48% YoY. Adjusted PAT rose 60% YoY to INR5.9b (est. of INR5.7b).
- Chemicals** revenue (42% of total sales in FY22) grew 36% YoY to INR15.7b in 4QFY22, with EBIT growth of 83% YoY to INR5.0b. EBIT margin expanded 820bp YoY to 32.1% due to the strong performance of the **Fluorochemicals Business** aided by higher sales realizations from the refrigerants and chloromethane segments in domestic as well as export markets. The strong demand for flagship products and downstream derivatives augured well for the **Specialty Chemicals Business**.
- Packaging Film** revenue (38% of total sales in FY22) grew 42% YoY to INR13.9b in 4QFY22 and EBIT was up 26% YoY to INR2.8b. However, margin contracted 250bp YoY to 19.8%. The demand of BOPET as well as BOPP films remained buoyant. The segment performance was strong in the overseas markets. The company has benefited from higher volumes from the recent capitalizations of the BOPET plant in Hungary and BOPP plant in Thailand.
- Technical Textiles** revenue (17% of total sales in FY22) grew 24% YoY to INR5.0b in 4QFY22. EBIT margin remained relatively flat YoY at 18.4%, while EBIT grew 26% YoY to INR914m. The segment witnessed strong growth in the Belting Fabrics and the Polyester Industrial Yarn segments, partially offsetting the weak demand for Nylon Tyre Cord Fabrics during the quarter.
- In FY22, revenue/EBITDA/adjusted PAT grew 48%/45%/58%, respectively. CFO for FY22 came in at INR21.1b, up 19% YoY. CFO/EBITDA stood at 68% v/s 83% in FY21.

Highlights from the management commentary

- Growth guidance in specialty chemicals:** In FY22, specialty chemicals revenue grew 30% (to INR31b) whereas the company has guided for revenue growth of 20% in FY23.
- Fluorochemicals business:** Demand scenario for refrigerants and Pharma segment is likely to remain healthy. HFC plant capacity utilization for FY22 was in the range of 70-75%.

Sumant Kumar - Research Analyst (Sumant.Kumar@MotilalOswal.com)

Research Analyst: Meet Jain (meet.jain@motilalosal.com) / Pranav Lala (Pranav.lala@motilalosal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

 Motilal Oswal research is available on www.motilalosal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- **Chemicals segment margin:** The company expects the Chemicals EBIT margin of 26.7% in FY22 to sustain and grow in FY23.
- **Capex:** FY23 capex will be in the range of INR25-27b (out of a total capex, INR17-18b is in Chemical segment, INR 11-12b in Fluorochemicals and INR 6-7b in Specialty Chemical). The company will setup dedicated facilities to produce key specialty products in the new plant structure at Dahej at an estimated cost of INR1.2b. It has also planned for a capacity expansion of R22 at Dahej at an approximate cost of INR300m.

Valuation and view

- Chemicals EBIT margin in FY22 was 26.7% primarily due to higher refrigerants realizations in domestic as well as export markets. We expect the margin trajectory of chemicals business will be sustained at/above FY22 levels. We anticipate Packaging Films business' EBIT margin to decline to 18.5%/18.0% in FY23/FY24, respectively, from 19.8% in FY22 due to expected pressure on BOPET margins with new capacities coming on-stream. Going forward, we project SRF to post a revenue/EBITDA/PAT CAGR of 15%/15%/17% over FY22-24E, respectively.
- Factoring in 4QFY22 performance with higher-than-estimated Chemicals EBIT, we upgrade our FY23E/FY24E earnings by 14%/8%, respectively.
- We are encouraged by the long-term structural opportunity in the Chemicals sector. While we certainly believe the company can cash-in on these opportunities, we maintain our **Neutral** stance owing to high valuations, which have been priced into the near-term upside.

Consolidated - Quarterly Earning Model

(INR m)


Y/E March	FY21				FY22				FY21	FY22	FY22E 4QFY22	Var %
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
Net Sales	15,452	21,008	21,464	26,077	26,994	28,390	33,459	35,494	84,000	1,24,337	35,278	1
YoY Change (%)	-12.4	20.9	16.0	40.4	74.7	35.1	55.9	36.1	16.5	48.0	33.1	
Total Expenditure	11,728	15,188	16,018	19,734	20,350	21,846	24,980	26,128	62,667	93,305	26,167	
EBITDA	3,723	5,821	5,446	6,343	6,644	6,544	8,479	9,366	21,333	31,032	9,110	3
Margins (%)	24.1	27.7	25.4	24.3	24.6	23.0	25.3	26.4	25.4	25.0	25.8	
Depreciation	1,040	1,140	1,166	1,185	1,230	1,303	1,324	1,316	4,531	5,172	1,410	
Interest	432	362	285	262	275	234	294	357	1,340	1,159	295	
Other Income	101	98	217	130	138	111	107	72	545	428	130	
PBT before EO expense	2,353	4,417	4,213	5,026	5,277	5,118	6,968	7,765	16,008	25,128	7,535	
Extra-Ord expense & DO	89	101	-220	-85	-72	-206	-335	-114	-116	-727	0	
PBT	2,264	4,316	4,432	5,111	5,349	5,324	7,303	7,879	16,123	25,856	7,535	
Tax	493	1,164	1,185	1,302	1,396	1,500	2,247	1,823	4,144	6,966	1,808	
Rate (%)	21.0	26.4	28.1	25.9	26.5	29.3	32.3	23.5	25.9	27.7	24.0	
Reported PAT	1,771	3,152	3,247	3,809	3,953	3,825	5,055	6,057	11,979	18,889	5,727	
Adj PAT	1,860	3,253	3,028	3,724	3,881	3,619	4,720	5,943	11,864	18,162	5,727	4
YoY Change (%)	16.0	58.6	-9.0	68.3	108.7	11.2	55.9	59.6	29.0	53.1	38.1	
Margins (%)	12.0	15.5	14.1	14.3	14.4	12.7	14.1	16.7	14.1	14.6	14.8	

Key Performance Indicators

Y/E March	FY21				FY22				FY21	FY22
Consolidated	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
Segment Revenue Growth (%)										
Technical Textile	-63.2	2.9	9.3	26.5	251.0	67.8	46.5	24.0	-8.6	68.1
Chemicals & Polymers	16.9	30.0	11.6	30.7	57.9	27.8	57.7	36.4	22.5	43.8
Packaging Film	-3.5	25.7	25.7	62.8	53.7	28.7	59.1	41.9	26.4	45.2
Segment EBIT Margins (%)										
Technical Textile	-10.0	15.1	18.5	18.2	27.1	23.8	21.1	18.4	14.3	22.6
Chemicals & Polymers	12.6	19.8	21.0	23.9	20.0	22.3	29.4	32.1	20.0	26.7
Packaging Film	32.6	29.6	26.5	22.3	22.7	16.7	19.9	19.8	27.3	19.8
Cost Break-up										
RM Cost (% of sales)	48.0	45.5	47.5	50.0	49.3	50.4	49.1	46.9	47.8	48.8
Staff Cost (% of sales)	8.9	7.2	7.4	6.7	6.7	6.3	6.2	6.0	7.4	6.3
Power and Fuel Cost (% of sales)	8.0	9.0	9.1	8.0	8.6	9.3	9.0	9.6	8.5	9.1
Other Cost (% of sales)	11.0	10.6	10.7	10.9	10.7	11.0	10.4	11.2	10.8	10.8
Gross Margins (%)	52.0	54.5	52.5	50.0	50.7	49.6	50.9	53.1	52.2	51.2
EBITDA Margins (%)	24.1	27.7	25.4	24.3	24.6	23.0	25.3	26.4	25.4	25.0
EBIT Margins (%)	17.4	22.3	19.9	19.8	20.1	18.5	21.4	22.7	20.0	20.8


Key exhibits

Exhibit 1: Consolidated revenue trend




Source: Company, MOFSL

Exhibit 2: Consolidated EBITDA trend




Source: Company, MOFSL

Exhibit 3: Consolidated adjusted PAT trend




Source: Company, MOFSL

Exhibit 4: Revenue mix trend




Source: Company, MOFSL

Exhibit 5: EBIT mix trend




Source: Company, MOFSL

Exhibit 6: Revenue trend in Chemicals




Source: Company, MOFSL

Exhibit 7: EBIT trend in Chemicals




Source: Company, MOFSL

Exhibit 8: Revenue trend in Packaging Film




Source: Company, MOFSL

Exhibit 9: EBIT trend in Packaging Film




Source: Company, MOFSL

Exhibit 10: Revenue trend in Technical Textiles



Source: Company, MOFSL

Exhibit 11: EBIT trend in Technical Textiles



Source: Company, MOFSL



Key highlights from the management commentary

Chemicals segment

- The Fluorochemicals business performed very well during the quarter due to higher sales realizations from the refrigerants and chloromethanes segments, in both the domestic and export markets. The business saw volumes being sustained during the quarter. HFC plant capacity utilization for FY22 was in the range of 70-75%.
- The segment witnessed a strong demand for Dymel® HFA 134a/P. The business is expanding presence across India, Bangladesh, Argentina, and Thailand. It has also entered new markets such as Greece and Taiwan.
- Specialty Chemicals business saw a strong demand for flagship products and downstream derivatives. The company has continued to focus on enhancing new product portfolio with six new products launched during the year.
- **Capacities:** SRF has an R32 capacity of 14,000MTPA, R134 of 20,000MTPA and a swing plant with +/- 4,000MTPA. R125 capacity is at 7,000MTPA and R22 is at 17,500MTPA with additions of 25,000MTPA planned for FY23.
- **Outlook:** The healthy demand across refrigerants and pharmaceuticals segment would continue to auger well for the Fluorochemicals business. Global agrochemical innovators continue to witness healthy growth across key markets, which will lead to better demand for specialty product. Severe inflationary pressures on prices of key raw materials and utilities along with logistics challenges and global supply chain disruption would remain key concerns for the business.
- **Guidance:** SRF believes it can achieve a growth of upwards of 20% in FY23 on account of strong product mix and increased market reach. It expects the Chemical EBIT margin of 26.7% in FY22 to sustain/grow in FY23.

Packaging Film segment

- The demand for both BOPET and BOPP films remained buoyant. The segment performed extremely well in the overseas markets, on the back of higher volumes from recent capitalizations of the BOPET plant in Hungary and BOPP plant in Thailand. Increasing sales growth from Value-Added Products (VAP) further enhanced overall performance.
- The management anticipates a strong BOPP demand in the future. Margins could see certain pressures with commissioning of several new BOPET lines in India and high logistics costs and supply chain-related constraints.
- The company has established a subsidiary in aluminum to distinguish its brand and exercise sourcing and cost synergies. The company would soon commence the construction of the aluminum foil plant through its Altech Ltd subsidiary.
- Capacity for packaging films is currently at 310,000MTPA out of which 60,000MTPA of BOPP is being commissioned that would be added by end of this fiscal.

Technical Textiles segment

- The segment witnessed strong growth in the Belting Fabrics and the Polyester Industrial Yarn segments, partially offsetting the weak demand for Nylon Tyre Cord Fabrics during the quarter.

- The management anticipates healthy demand with improving Indian economy and re-opening of the mining sector; the belting segment would continue to see a robust demand. Replacement demand sales are likely to be positive in the upcoming quarters.
- **Coated fabrics:** Domestic demand that was slow initially due to the deferment of orders is now picking up and is expected to firm up considerably. SRF continues to be a leader in the domestic market.
- **Laminated fabrics:** Although realizations in this segment were adversely impacted by the continuing surplus supply situation, SRF was able to maintain its price & volume leadership with plant operating at full capacity, achieving its highest ever sales in Q4 FY 22
- **Guidance:** SRF is confident of witnessing stronger EBIT margins in the segment and believes that an EBIT of INR1b to INR1.2b would be sustainable over the long term.

Other highlights

- **Price hikes:** SRF is constantly renegotiating the contracts on regular intervals and aims to secure itself for the next year in terms of pricing. The company has passed on 30% of costs in chemicals and can move up to 65% odd levels.
- **Interest:** Although net debt has decreased, the interest cost is likely to increase by 50bp or so in line with the global market. The company aims to hedge this risk through securing rates and focus on managing liquidity.
- **Capex:** FY23 capex will be in the range of INR25-27b (out of a total capex, INR17-18b is in Chemical segment, INR 11-12b in Fluorochemicals and INR 6-7b in Specialty Chemical). The company will setup dedicated facilities to produce key specialty products in the new plant structure at Dahej at an estimated cost of INR1.2b. It has also planned for a capacity expansion of R22 at Dahej at an approximate cost of INR300m.
- **Downstream products:** SRF would commission PTFE project by Oct'22 with the INR300m capex being utilized for debottlenecking and enhancing downstream R22 portfolio in order to address the market gaps.

Valuation and view

- Chemicals EBIT margin in FY22 was 26.7% primarily due to higher refrigerants realizations in domestic as well as export markets. We expect the margin trajectory of chemicals business will be sustained at/above FY22 levels. We anticipate Packaging Films business' EBIT margin to decline to 18.5%/18.0% in FY23/FY24, respectively, from 19.8% in FY22 due to expected pressure on BOPET margins with new capacities coming on-stream. Going forward, we project SRF to post a revenue/EBITDA/PAT CAGR of 15%/15%/17% over FY22-24E, respectively.
- Factoring in 4QFY22 performance with higher-than-estimated Chemicals EBIT, we upgrade our FY23E/FY24E earnings by 14%/8%, respectively.
- We are encouraged by the long-term structural opportunity in the Chemicals sector. While we certainly believe the company can cash-in on these opportunities, we maintain our **Neutral** stance owing to high valuations, which have been priced into the near-term upside.

Exhibit 12: Valuation methodology

EV/EBITDA	FY24 EBITDA (INRm)	Multiple (x)	EV (INRm)
Technical Textiles	4,884	10	48,842
Chemicals & Polymers	24,758	23	5,69,430
Packaging Films	12,668	10	1,26,682
Others	537	5	2,685
Total EV			7,47,639
Less: Debt			32,394
Less: Minority Interest			-
Add: Cash & Cash Equivalents			3,108
Target Mcap (INR m)			7,18,353
Outstanding share (m)			297.4
Target Price (INR)			2,415

Source: MOFSL

Exhibit 13: Revisions to our estimates

Earnings Change (INR m)	Old		New		Change (%)	
	FY23E	FY24E	FY23E	FY24E	FY23E	FY24E
Revenue	1,34,371	1,52,755	1,45,029	1,64,007	8	7
EBITDA	32,913	37,700	36,516	40,783	11	8
Adj. PAT	19,825	23,080	22,510	24,995	14	8

Source: MOFSL

Financials and valuations

Consolidated - Income Statement

(INR Million)

Y/E March	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E
Total Income from Operations	45,927	48,218	55,890	70,996	72,094	84,000	1,24,337	1,45,029	1,64,007
Change (%)	1.2	5.0	15.9	27.0	1.5	16.5	48.0	16.6	13.1
EBITDA	9,728	9,694	9,062	13,209	14,584	21,333	31,032	36,516	40,783
Margin (%)	21.2	20.1	16.2	18.6	20.2	25.4	25.0	25.2	24.9
Depreciation	2,750	2,834	3,158	3,582	3,886	4,531	5,172	5,972	7,097
EBIT	6,979	6,859	5,904	9,627	10,698	16,803	25,860	30,544	33,686
Int. and Finance Charges	1,305	1,018	1,239	1,984	2,007	1,340	1,159	1,221	1,169
Other Income	278	730	688	280	491	545	428	492	591
PBT bef. EO Exp.	5,952	6,572	5,353	7,923	9,182	16,008	25,128	29,815	33,107
EO Items	-103	0	463	262	997	116	727	0	0
PBT after EO Exp.	5,849	6,572	5,817	8,185	10,179	16,123	25,856	29,815	33,107
Current Tax	1,551	1,422	1,200	1,769	265	4,154	7,139	7,306	8,112
Deferred Tax	0	0	0	0	-277	-10	-173	0	0
Tax Rate (%)	26.5	21.6	20.6	21.6	-0.1	25.7	26.9	24.5	24.5
Less: Mionrity Interest	0	0	0	0	0	0	0	0	0
Reported PAT	4,299	5,150	4,617	6,416	10,191	11,979	18,889	22,510	24,995
Adjusted PAT	4,402	5,150	4,154	6,155	9,194	11,864	18,162	22,510	24,995
Change (%)	45.4	17.0	-19.3	48.2	49.4	29.0	53.1	23.9	11.0
Margin (%)	9.6	10.7	7.4	8.7	12.8	14.1	14.6	15.5	15.2

Consolidated - Balance Sheet

(INR Million)

Y/E March	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E
Equity Share Capital	574	574	575	575	585	603	2,974	2,974	2,974
Total Reserves	27,055	31,252	35,071	40,718	48,748	67,962	82,679	1,00,132	1,20,071
Net Worth	27,630	31,826	35,646	41,293	49,333	68,564	85,654	1,03,107	1,23,046
Minority Interest	0	0	0	0	0	0	0	0	0
Deferred Liabilities	3,820	2,866	2,914	3,420	1,755	3,862	6,775	6,775	6,775
Total Loans	25,153	23,962	31,418	37,302	40,468	33,950	35,394	34,394	32,394
Capital Employed	56,602	58,655	69,978	82,014	91,556	1,06,376	1,27,822	1,44,275	1,62,214
Gross Block	71,410	77,169	87,502	68,322	76,934	96,167	1,06,943	1,31,943	1,51,943
Less: Accum. Deprn.	30,334	33,169	36,327	12,269	15,540	20,071	25,243	31,215	38,313
Net Fixed Assets	41,076	44,000	51,175	56,053	61,394	76,096	81,699	1,00,727	1,13,630
Goodwill on Consolidation	49	49	41	41	6	6	0	0	0
Capital WIP	1,174	2,586	5,588	7,536	13,933	7,723	16,716	18,716	18,716
Current Investments	1,606	1,708	1,217	1,005	1,985	4,125	3,167	1,667	1,667
Total Investments	1,649	1,959	1,218	1,006	2,027	4,167	3,209	1,709	1,709
Curr. Assets, Loans&Adv.	20,291	21,090	25,608	34,243	31,265	41,121	56,025	56,554	65,587
Inventory	6,711	8,381	9,582	12,247	12,012	14,658	21,385	20,634	23,317
Account Receivables	5,145	6,569	6,807	10,288	8,911	12,746	17,925	17,880	20,220
Cash and Bank Balance	3,399	961	967	1,989	1,255	2,820	4,594	2,887	3,108
Loans and Advances	5,036	5,178	8,252	9,719	9,088	10,898	12,123	15,153	18,942
Curr. Liability & Prov.	8,934	11,055	13,653	16,865	17,211	22,918	29,944	33,548	37,544
Account Payables	7,146	8,089	10,442	13,824	11,117	15,852	20,964	23,308	26,340
Other Current Liabilities	1,477	2,606	2,831	2,600	5,653	6,544	8,391	9,650	10,615
Provisions	312	359	380	441	442	522	590	590	590
Net Current Assets	11,357	10,035	11,955	17,378	14,054	18,203	26,081	23,006	28,042
Appl. of Funds	56,603	58,655	69,978	82,014	91,556	1,06,376	1,27,822	1,44,275	1,62,214

Financials and valuations

Ratios

Y/E March	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E
Basic (INR)									
EPS	14.8	17.3	14.0	20.7	30.9	39.9	61.1	75.7	84.0
Cash EPS	24.0	26.8	24.6	32.7	44.0	55.1	78.5	95.8	107.9
BV/Share	92.9	107.0	119.8	138.8	165.9	230.5	288.0	346.6	413.7
DPS	1.9	2.3	3.1	3.9	2.8	4.9	16.8	17.0	17.0
Payout (%)	15.2	15.7	23.1	20.8	9.6	12.1	26.4	22.5	20.2
Valuation (x)									
P/E	142.7	122.0	151.2	102.1	68.3	52.9	34.6	27.9	25.1
Cash P/E	87.8	78.7	85.9	64.5	48.0	38.3	26.9	22.1	19.6
P/BV	22.7	19.7	17.6	15.2	12.7	9.2	7.3	6.1	5.1
EV/Sales	14.1	13.5	11.8	9.3	9.2	7.8	5.3	4.5	4.0
EV/EBITDA	66.6	67.0	72.5	50.2	45.6	30.7	21.1	18.0	16.1
Dividend Yield (%)	0.1	0.1	0.1	0.2	0.1	0.2	0.8	0.8	0.8
FCF per share	17.2	0.2	-20.3	-5.3	-2.3	19.1	9.7	13.7	28.4
Return Ratios (%)									
EBITDA Margins (%)	21.2	20.1	16.2	18.6	20.2	25.4	25.0	25.2	24.9
Net Profit Margins (%)	9.6	10.7	7.4	8.7	12.8	14.1	14.6	15.5	15.2
RoE	17.0	17.3	12.3	16.0	20.3	20.1	23.6	23.9	22.1
RoCE	10.5	11.0	8.5	10.7	13.3	13.4	17.2	18.1	17.7
RoIC	18.5	17.8	13.8	18.0	15.3	26.3	34.2	34.5	32.9
Working Capital Ratios									
Fixed Asset Turnover (x)	0.6	0.6	0.6	1.0	0.9	0.9	1.2	1.1	1.1
Asset Turnover (x)	0.8	0.8	0.8	0.9	0.8	0.8	1.0	1.0	1.0
Inventory (Days)	105	126	115	113	119	133	129	108	108
Debtor (Days)	41	50	44	53	45	55	53	45	45
Creditor (Days)	112	122	126	127	110	144	126	122	122
Leverage Ratio (x)									
Debt/Equity	0.9	0.8	0.9	0.9	0.8	0.5	0.4	0.3	0.3

Consolidated - Cash Flow Statement

(INR Million)

Y/E March	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E
OP/(Loss) before Tax	5,849	6,572	5,817	8,269	10,706	16,099	25,856	29,815	33,107
Depreciation	2,750	2,834	3,158	3,669	3,929	4,531	5,172	5,972	7,097
Interest & Finance Charges	1,305	1,018	1,239	2,016	2,016	1,340	1,159	1,221	1,169
Direct Taxes Paid	-1,087	-1,159	-1,176	-1,502	-1,427	-2,553	-4,016	-7,306	-8,112
(Inc)/Dec in WC	2,214	-2,556	-1,909	-3,165	-239	-1,236	-6,645	1,368	-4,815
CF from Operations	11,030	6,709	7,129	9,286	14,984	18,181	21,527	31,071	28,446
Others	-130	-255	-349	-330	-1,940	-464	-469	0	0
CF from Operating incl EO	10,901	6,454	6,780	8,956	13,044	17,717	21,057	31,071	28,446
(inc)/dec in FA	-5,789	-6,409	-12,829	-10,526	-13,730	-12,047	-18,171	-27,000	-20,000
Free Cash Flow	5,112	45	-6,049	-1,570	-685	5,670	2,886	4,071	8,446
(Pur)/Sale of Investments	-576	25	840	332	-886	-1,886	1,028	1,500	0
Others	-303	251	35	53	2,813	-1,064	1,265	0	0
CF from Investments	-6,667	-6,133	-11,953	-10,142	-11,803	-14,997	-15,877	-25,500	-20,000
Issue of Shares	0	0	0	1	0	7,500	2	0	0
Inc/(Dec) in Debt	637	-4,552	4,095	2,677	3,205	-6,856	622	-1,000	-2,000
Interest Paid	-1,324	-1,109	-1,299	-2,241	-2,040	-1,574	-1,173	-1,221	-1,169
Dividend Paid	-692	-829	-829	-836	-803	-1,408	-2,117	-5,056	-5,056
Others	-528	3,731	3,213	2,606	-2,337	1,182	-741	0	0
CF from Fin. Activity	-1,907	-2,760	5,179	2,207	-1,975	-1,155	-3,406	-7,278	-8,225
Inc/Dec of Cash	2,326	-2,438	6	1,021	-734	1,565	1,774	-1,706	221
Opening Balance	1,073	3,399	961	967	1,989	1,255	2,820	4,594	2,887
Closing Balance	3,399	961	967	1,989	1,255	2,820	4,594	2,887	3,108

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOFSL is a subsidiary company of Passionate Investment Management Pvt. Ltd.. (PIMPL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company
- received compensation/other benefits from the subject company in the past 12 months
- other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 71934200/ 022-71934263; Website www.motilaloswal.com CIN no.: L67190MH2005PLC153397. Correspondence Office Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad(West), Mumbai- 400 064. Tel No: 022 7188 1000.

Registration Nos.: Motilal Oswal Financial Services Limited (MOFSL)*: INZ000158836(BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN - 146822; Investment Adviser: INA000007100; Insurance Corporate Agent: CA0579;PMS:INP000006712. Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP000000670); PMS and Mutual Funds are offered through MOAMC which is group company of MOFSL. Motilal Oswal Wealth Management Ltd. (MOWML): PMS (Registration No.: INP000004409) is offered through MOWML, which is a group company of MOFSL. Motilal Oswal Financial Services Limited is a distributor of Mutual Funds, PMS, Fixed Deposit, Bond, NCDs, Insurance Products and IPOs. Real Estate is offered through Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. which is a group company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Ltd which is a group company of MOFSL. Research & Advisory services is backed by proper research. Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market is subject to market risk, read all the related documents carefully before investing. Details of Compliance Officer: Name: Neeraj Agarwal, Email ID: na@motilaloswal.com, Contact No.:022-71881085.

* MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench.